JP6323629B1 - Ｅｐ４拮抗薬と免疫チェックポイント阻害薬を含んでなる組み合わせ - Google Patents

Ｅｐ４拮抗薬と免疫チェックポイント阻害薬を含んでなる組み合わせ Download PDF

Info

Publication number
JP6323629B1
JP6323629B1 JP2017559144A JP2017559144A JP6323629B1 JP 6323629 B1 JP6323629 B1 JP 6323629B1 JP 2017559144 A JP2017559144 A JP 2017559144A JP 2017559144 A JP2017559144 A JP 2017559144A JP 6323629 B1 JP6323629 B1 JP 6323629B1
Authority
JP
Japan
Prior art keywords
antibody
amino
cyclopropane
carbonyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017559144A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2018008711A1 (ja
Inventor
隆雄 吉田
隆雄 吉田
彰子 正山
彰子 正山
裕嗣 高野
裕嗣 高野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Application granted granted Critical
Publication of JP6323629B1 publication Critical patent/JP6323629B1/ja
Publication of JPWO2018008711A1 publication Critical patent/JPWO2018008711A1/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2017559144A 2016-07-07 2017-07-06 Ｅｐ４拮抗薬と免疫チェックポイント阻害薬を含んでなる組み合わせ Active JP6323629B1 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662359504P 2016-07-07 2016-07-07
US62/359,504 2016-07-07
PCT/JP2017/024753 WO2018008711A1 (ja) 2016-07-07 2017-07-06 Ｅｐ４拮抗薬と免疫チェックポイント阻害薬を含んでなる組み合わせ

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018053140A Division JP7020218B2 (ja) 2016-07-07 2018-03-20 Ｅｐ４拮抗薬と免疫チェックポイント阻害薬を含んでなる組み合わせ

Publications (2)

Publication Number Publication Date
JP6323629B1 true JP6323629B1 (ja) 2018-05-16
JPWO2018008711A1 JPWO2018008711A1 (ja) 2018-07-05

Family

ID=60912958

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017559144A Active JP6323629B1 (ja) 2016-07-07 2017-07-06 Ｅｐ４拮抗薬と免疫チェックポイント阻害薬を含んでなる組み合わせ
JP2018053140A Active JP7020218B2 (ja) 2016-07-07 2018-03-20 Ｅｐ４拮抗薬と免疫チェックポイント阻害薬を含んでなる組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018053140A Active JP7020218B2 (ja) 2016-07-07 2018-03-20 Ｅｐ４拮抗薬と免疫チェックポイント阻害薬を含んでなる組み合わせ

Country Status (21)

Country Link
US (1) US11065226B2 (https=)
EP (1) EP3482760B1 (https=)
JP (2) JP6323629B1 (https=)
KR (1) KR102473601B1 (https=)
CN (1) CN109475520B (https=)
AU (1) AU2017292522B2 (https=)
CA (1) CA3029611A1 (https=)
DK (1) DK3482760T3 (https=)
ES (1) ES2900306T3 (https=)
HU (1) HUE057799T2 (https=)
IL (1) IL264063B (https=)
MX (1) MX385428B (https=)
MY (1) MY197673A (https=)
PH (1) PH12019500002B1 (https=)
PL (1) PL3482760T3 (https=)
PT (1) PT3482760T (https=)
RU (1) RU2748731C2 (https=)
SG (1) SG11201811591UA (https=)
TW (2) TWI795362B (https=)
WO (1) WO2018008711A1 (https=)
ZA (1) ZA201900060B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3255624B2 (ja) 1998-07-03 2002-02-12 日本電信電話株式会社 コネクタプラグおよび光コネクタ

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ733575A (en) * 2015-01-09 2022-10-28 Ono Pharmaceutical Co Tricyclic spiro compound
AU2018255300B2 (en) * 2017-04-18 2021-10-28 Tempest Therapeutics, Inc. Bicyclic compounds and their use in the treatment of cancer
JP7159007B2 (ja) 2017-11-01 2022-10-24 小野薬品工業株式会社 脳腫瘍の治療のための医薬
US20200352906A1 (en) * 2018-02-05 2020-11-12 Shenzhen Ionova Life Science Co., Ltd. Heterobicyclic Carboxylic Acids for Treating Cancer or Inflammatory Diseases
CN110156674A (zh) * 2018-02-13 2019-08-23 中国科学院上海有机化学研究所 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物
US10973834B2 (en) * 2018-04-16 2021-04-13 Arrys Therapeutics, Inc. EP4 inhibitors and use thereof
IL277963B2 (en) 2018-04-17 2024-09-01 Tempest Therapeutics Inc Bicyclic carboxamides and methods of use thereof
US20210315909A1 (en) 2018-07-11 2021-10-14 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
EP3722319A1 (en) * 2019-04-09 2020-10-14 Rottapharm Biotech S.r.l. Pharmaceutical combination of an ep4 antagonist and immune checkpoint inhibitors for the treatment of tumours
WO2020242773A1 (en) * 2019-05-31 2020-12-03 Clear Creek Bio, Inc. Methods of promoting differentiation of myeloid-derived suppressor cells using inhibitors of dihydroorotate dehydrogenase
CN110386941A (zh) * 2019-08-15 2019-10-29 上海邦耀生物科技有限公司 Ep4受体拮抗剂和pd-1抑制剂联合用于癌症的治疗
KR20220122696A (ko) * 2019-12-25 2022-09-02 니뽄 신야쿠 가부시키가이샤 면역 체크포인트 저해제와 병용으로 이용하는 항종양약
WO2021183640A1 (en) * 2020-03-10 2021-09-16 Emory University Methods of treating cancer using checkpoint inhibitors in combination with purine cleaving enzymes
US20230390303A1 (en) 2020-11-13 2023-12-07 Ono Pharmaceutical Co., Ltd. Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor
CN117377656A (zh) * 2021-05-28 2024-01-09 南京明德新药研发有限公司 苯并螺杂环衍生物及其应用
US20250002448A1 (en) * 2021-09-21 2025-01-02 Merck Sharp & Dohme Llc Allosteric modulators of nicotinic acetylcholine receptors
WO2023198060A1 (zh) * 2022-04-12 2023-10-19 正大天晴药业集团股份有限公司 蛋白酶体抑制剂与抗pd-1抗体的药物组合

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016311A1 (en) * 2000-08-22 2002-02-28 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives, process for producing the same and drugs containing the same as the active ingredient
WO2015179615A1 (en) * 2014-05-23 2015-11-26 Eisai R&D Management Co., Ltd Combination therapies for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1071648A2 (en) 1998-03-13 2001-01-31 Merck Frosst Canada & Co. Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
US6211197B1 (en) 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
MXPA04001253A (es) 2001-08-09 2004-06-03 Ono Pharmaceutical Co Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
JP5301469B2 (ja) 2007-02-26 2013-09-25 メルク カナダ インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体
US20150004175A1 (en) 2011-12-13 2015-01-01 Yale University Compositions and Methods for Reducing CTL Exhaustion
NZ733575A (en) 2015-01-09 2022-10-28 Ono Pharmaceutical Co Tricyclic spiro compound

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016311A1 (en) * 2000-08-22 2002-02-28 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives, process for producing the same and drugs containing the same as the active ingredient
WO2015179615A1 (en) * 2014-05-23 2015-11-26 Eisai R&D Management Co., Ltd Combination therapies for the treatment of cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3255624B2 (ja) 1998-07-03 2002-02-12 日本電信電話株式会社 コネクタプラグおよび光コネクタ

Also Published As

Publication number Publication date
AU2017292522A9 (en) 2019-01-31
KR20190026736A (ko) 2019-03-13
TWI795362B (zh) 2023-03-11
PL3482760T3 (pl) 2022-02-07
IL264063B (en) 2022-02-01
JP2018100297A (ja) 2018-06-28
US20190255013A1 (en) 2019-08-22
JP7020218B2 (ja) 2022-02-16
WO2018008711A1 (ja) 2018-01-11
JPWO2018008711A1 (ja) 2018-07-05
SG11201811591UA (en) 2019-01-30
AU2017292522B2 (en) 2022-10-13
CN109475520B (zh) 2021-05-14
TW202224675A (zh) 2022-07-01
ES2900306T3 (es) 2022-03-16
PT3482760T (pt) 2021-12-15
RU2018146479A (ru) 2020-08-07
NZ749540A (en) 2024-09-27
KR102473601B1 (ko) 2022-12-01
PH12019500002B1 (en) 2024-06-28
RU2018146479A3 (https=) 2020-11-23
ZA201900060B (en) 2019-09-25
CN109475520A (zh) 2019-03-15
AU2017292522A1 (en) 2019-01-17
BR112019000243A2 (pt) 2019-04-16
EP3482760B1 (en) 2021-11-10
TWI805255B (zh) 2023-06-11
CA3029611A1 (en) 2018-01-11
MX2018015567A (es) 2019-06-06
DK3482760T3 (da) 2022-01-03
EP3482760A1 (en) 2019-05-15
IL264063A (en) 2019-01-31
HUE057799T2 (hu) 2022-06-28
US11065226B2 (en) 2021-07-20
RU2748731C2 (ru) 2021-05-31
MY197673A (en) 2023-07-03
PH12019500002A1 (en) 2019-10-21
MX385428B (es) 2025-03-04
TW201806593A (zh) 2018-03-01
EP3482760A4 (en) 2019-07-10

Similar Documents

Publication Publication Date Title
JP6323629B1 (ja) Ｅｐ４拮抗薬と免疫チェックポイント阻害薬を含んでなる組み合わせ
US12497377B2 (en) Tricyclic spiro compound
JP6269888B1 (ja) 医薬用途
CA2973330C (en) Tricyclic spiro compound
BR112019000243B1 (pt) Medicamento compreendendo uma combinação de um composto antagonista do ep4 e um inibidor de checkpoint imunológico, bem como uso da referida combinação para o tratamento de câncer
HK40002610A (en) Combination comprising ep4 antagonist and immune checkpoint inhibitor
HK40002610B (zh) 包含ep4拮抗剂和免疫检查点抑制剂的组合
NZ789384A (en) Combination comprising EP4 antagonist and immune checkpoint inhibitor
HK1239657B (zh) 三环螺环化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171110

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20171110

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20171129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180313

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180326

R150 Certificate of patent or registration of utility model

Ref document number: 6323629

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250